Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Grabowska, Joanna" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1065267.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    complications of oncological therapy
    non-pegylated liposomal doxorubicin
    Opis:
    Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.
    Źródło:
    OncoReview; 2015, 5, 3; A103-108
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The use of fulvestrant in patients with advanced breast cancer
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1035843.pdf
    Data publikacji:
    2018
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    fulvestrant
    hormone therapy
    Opis:
    Breast cancer is the most common malignancy in women in Poland and the entire world, but thanks to early diagnostics and efficacious therapeutic methods, its prognosis is good. In some patients with advanced breast cancer, long-term survival is observed, which is why it is essential to select the most appropriate therapy, and to follow up on the course of disease and possible adverse events related to the treatment applied. The slow development of hormone-receptor-positive cancer, and a multitude of therapeutic options constitute a real challenge in palliative treatment. The use of fulvestrant resulted in a good response in both of the presented cases, and did not in any way comprise the daily lives of the patients over a long period of time.
    Źródło:
    OncoReview; 2018, 8, 1; 15-18
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cardiovascular complications of selected antibodies used in oncological immunotherapy
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062897.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    bevacizumab
    immunotherapy
    monoclonal antibodies
    pertuzumab
    trastuzumab
    trastuzumab-emtansine
    vascular endothelial growth factor
    Opis:
    Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms that block the immune system, and direct destruction of neoplastic cells. Different from chemotherapy or hormonal therapy, its mechanism of action is associated with a different profile of adverse events. HER2 receptor inhibitors may cause symptoms of heart failure, which usually recede, once the treatment has been discontinued. Bevacizumab, an anti-VEGF antibody, induces numerous cardiovascular complications, including arterial hypertension, arterial embolism, haemorrhage and haemoptysis as well as venous thromboembolism.
    Źródło:
    OncoReview; 2017, 7, 2; 78-82
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Fertility and breast cancer
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1064776.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    breast cancer during pregnancy
    breast cancer in young women
    fertility
    fertility preservation strategies
    Opis:
    Breast cancer is the most common cancer among females worldwide. The mean age of breast cancer patients is > 60 yrs old, and it is seldom found in women < 40 yrs old (6.5%) and in very young women < 35 yrs old (0.6%). In young females, fertility and all its aspects are an additional therapeutic challenge. Before initiating treatment, the oncologist should offer effective contraception to be applied throughout the therapy, bearing in mind that fertility preservation is of utmost importance. When it comes to breast cancer in pregnancy, the attending physician should use a therapy which is safe for both the mother and the foetus. Chemotherapy, radiotherapy, hormonal therapy and immunotherapy can, to a lesser or greater degree, damage the ovarian function resulting in amenorrhea in women < 50 yrs (33–76%). However, owing to fertility preservation strategies, more and more pregnancies are successful, even in breast cancer survivors.
    Źródło:
    OncoReview; 2016, 6, 4; A157-161
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The young breast cancer patient therapy – new opportunities, new challenges
    Autorzy:
    Załuska-Kusz, Joanna
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1035689.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    breast cancer in young patient
    metastatic disease
    non-pegylated liposomal doxorubicin
    ribociclib
    Opis:
    The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.
    Źródło:
    OncoReview; 2019, 9, 2; 51-54
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy
    Autorzy:
    Wójcik, Elżbieta
    Kufel-Grabowska, Joanna
    Gierba-Tomczyk, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062503.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    non-pegylated liposomal doxorubicin
    treatment
    Opis:
    Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment. In the treatment of metastatic disease combination chemotherapy with doxorubicin provides the objective response rate of 60–85%, and the median time of progression-free survival is about 12 months. Non-pegylated liposomal doxorubicin (NPLD) in combination with cyclophosphamide is associated with a lower risk of cardiotoxicity, higher efficacy and more favourable toxicity profile as compared with conventional anthracycline regimes. Two cases of females patients treated with NPLD described in this article demonstrate the importance of the choice of chemotherapy, professional monitoring, early detection and treatment of adverse effects. Non-pegylated liposomal doxorubicin ordained in systemic treatment of stage IV breast cancer prolongs survival and enhances the quality of life. It is a reasonable option for palliative therapy.
    Źródło:
    OncoReview; 2017, 7, 4; 162-167
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Spectacular efficacy of neoadjuvant chemotherapy in a patient with cervical cancer of IB2 grade according to FIGO 2009
    Spektakularna skuteczność chemioterapii neoadiuwantowej u pacjentki z rozpoznaniem raka szyjki macicy w stopniu IB2 według FIGO 2009 r.
    Autorzy:
    Kaźmierczak, Kamila
    Nowakowski, Błażej
    Kufel-Grabowska, Joanna
    Cholewiński, Witold
    Powiązania:
    https://bibliotekanauki.pl/articles/1035650.pdf
    Data publikacji:
    2020
    Wydawca:
    Medical Education
    Tematy:
    cervical cancer
    neoadjuvant chemotherapy
    positron emission tomography
    Opis:
    The presented case report is an example of a spectacular effect of induction systemic treatment in a patient with locally advanced cervical cancer of IB2 grade according to FIGO 2009 (International Federation of Gynecologist and Obstetrician). The effect of induction chemotherapy (three series in paclitaxel/24 h + cisplatin regimen at an interval of three weeks) was the total metabolic response of the primary tumor and nodal lesions found in FDG-PET/CT (18F-fluorodeoxyglucose – positron emission tomography combined with computed tomography) as well as an image of total regression of the tumor in the obtained postoperative histopathological examination.
    Przedstawiony opis przypadku jest przykładem spektakularnego efektu zastosowania chemioterapii neoadiuwantowej (NACT, neoadjuvant chemotherapy) u pacjentki z miejscowo zaawansowanym rakiem szyjki macicy w stopniu IB2 według FIGO 2009 r. (International Federation of Gynecologist and Obstetrician). Efektem zastosowanej chemioterapii indukcyjnej (trzech serii w schemacie paklitaksel/24 h + cisplatyna w odstępie 3-tygodniowym) była całkowita odpowiedź metaboliczna guza pierwotnego i zmian węzłowych stwierdzona w badaniu FDG-PET/CT (18F-fluorodeoksyglukoza – pozytonowa tomografia emisyjna połączona z tomografią komputerową), a także obraz całkowitej odpowiedzi patologicznej w otrzymanym pooperacyjnym badaniu histopatologicznym.
    Źródło:
    OncoReview; 2020, 10, 2; 69-76
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Suspected ovarian cancer in a young patient with a congenital heart defect and a history of cardiac surgery and pacemaker implantation – difficult therapeutic decisions
    Autorzy:
    Kaźmierczak, Kamila
    Stempniewski, Tomasz
    Kufel-Grabowska, Joanna
    Nowakowski, Błażej
    Powiązania:
    https://bibliotekanauki.pl/articles/1035815.pdf
    Data publikacji:
    2018
    Wydawca:
    Medical Education
    Tematy:
    Ca 125 marker
    congenital heart defect
    endometriosis
    ovarian cancer
    Opis:
    After uterine cancer, ovarian cancer is the second most common female reproductive tract malignancy. In Poland, in 2015, there were 3735 new cases and 2738 deaths from ovarian cancer. Over 80% of all cases are diagnosed in women aged over 50, whereas only 6% – before 35 years of age. Most cases are diagnosed, when clinical symptoms have already appeared, and the disease is at least locally advanced. The case presented below describes a very young 28-year-old woman with a tumour in the pelvis, ascites and very high Ca 125 and HE 4 levels. The clinical symptoms as well as laboratory and imaging tests were suggestive of epithelial ovarian cancer that required urgent surgery due to progression of the disease. The surgery posed a significant risk of complications, but owing to the deterioration of the patient’s condition it was considered necessary. The patient was born with a severe, complex heart defect, had undergone two cardiac surgeries, and had a pacemaker (first VVIR, then DDD). She was also intensively treated for iatrogenic HCV infection and hypothyroidism. A multidisciplinary team (a gynecologist, cardiologist and anesthetist) were behind the decision to carry out a major gynecological operation which ended with success. For the past 6 years, the patient has been under constant oncological follow-up and enjoys a good health.
    Źródło:
    OncoReview; 2018, 8, 2; 38-41
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Ocular side effects of the taxane-based chemotherapy – do only vascular disorders matter?
    Autorzy:
    Rzeszotarska, Anna
    Stodolska-Nowak, Agata
    Kufel-Grabowska, Joanna
    Nowakowski, Błażej
    Kocięcki, Jarosław
    Powiązania:
    https://bibliotekanauki.pl/articles/1035681.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    chemotherapy
    ophthalmological complications
    taxanes
    Opis:
    Taxanes, whose mechanism of action is based on blocking the cells’ division of cells, have been commonly used in the chemotherapy process for over two decades. The indications for the use of taxanes include ovarian cancer, breast cancer, lung cancer, prostate cancer, some of gastrointestinal malignant tumors or Kaposi sarcoma. Currently, chemotherapy based on taxanes, as well as every cytostatic medicine, allows to improve survival outcomes in many patients with diagnosed malignancies, although it also involves the occurrence of adverse effects. These adverse events may be life-threatening or at least they can decline the patient’s quality of life. The main aim of this paper is to feature possible ocular side effects during taxane based chemotherapy. Physicians taking care of patients during chemotherapy based on taxanes, as well as on every other cytostatic medicine, should be aware of these probable ocular complications. An early diagnosis of ophthalmic complications caused by chemotherapy makes it possible to avoid long-lasting adverse effects.
    Źródło:
    OncoReview; 2019, 9, 3; 59-63
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience
    Autorzy:
    Buraczewska, Agnieszka
    Kardas, Joanna
    Młot, Beata
    Solarek, Wojciech
    Waśko-Grabowska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062936.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    cabozantinib
    hypothyroidism
    renal cell carcinoma
    Opis:
    Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
    Źródło:
    OncoReview; 2017, 7, 3; 121-125
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Chrom, Paweł
    Waśko-Grabowska, Anna
    Młot, Beata
    Szczylik, Cezary
    Powiązania:
    https://bibliotekanauki.pl/articles/773534.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    endothelial growth factor receptor
    non-small cell lung cancer
    tyrosine kinase inhibitor
    Opis:
    Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
    Źródło:
    OncoReview; 2017, 7, 2; 92-97
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies